A bill that would allow drug and device manufacturers to communicate off-label information about their products with payers cleared the House Energy & Commerce health subcommittee on Wednesday (Jan. 17), despite Democratic opposition. The bill allows health care economic information about an investigational product or investigational use of a medical product to be shared with payers, formularies or other similar entities without being considered false or misleading or a violation of the Food, Drug, and Cosmetic Act (FDCA) as long...